Approximately one-third of all approved drugs and one-half of all approved small molecule agents are enzyme inhibitors. This general class of therapies has demonstrated tremendous commercial potential with annual worldwide sales of over $65 billion. Through its review of the metalloenzyme literature, Viamet has determined that more than one-third of all clinically-validated enzyme targets are metalloenzymes and approximately 10% of all marketed drugs are metalloenzyme inhibitors. The primary focus at Viamet is to develop improved small molecule metalloenzyme inhibitors against validated targets whose current inhibitors are not optimal from a safety or efficacy perspective.

Utilizing its proprietary Metallophile^® Technology, Viamet has rapidly developed analogues of known metalloenzyme inhibitors by optimizing the metal-binding component of these small molecule inhibitors.  In the process, Viamet obtains new chemical entities with reduced chemistry and biology risk and reduced timeline to the clinic. The Metallophile Technology includes:

• Metallobase^®: a proprietary database of metalloenzymes and known metalloenzyme inhibitors;
• Metallophiles^®: novel and superior metal-binding groups; and
• Metallophile^® Indices: a series of proprietary, in silico predictive tools for the rapid selection of optimal Metallophiles for any given metalloenzyme target.

The Metallophile Technology allows Viamet to rapidly and predictably develop novel, small molecule inhibitors of key metalloenzymes which address deficiencies of current inhibitors through:

• Improved potency
• Improved safety
• Improved PK/ADME properties.

Utilizing the Metallophile Technology, Viamet has rapidly built a portfolio of proprietary clinical compounds and drug candidates that address significant unmet medical needs and have blockbuster commercial potential.